Growth Hormone

CJC-1295 (no DAC)

Modified Growth Hormone Releasing Factor (1-29) without Drug Affinity Complex

The shorter-acting GH secretagogue for pulsatile release

CJC-1295 without DAC (also called mod-GRF 1-29) is a modified growth hormone releasing hormone analogue that preserves natural pulsatile GH release patterns. It has a shorter half-life than the DAC version, making it popular for more physiological dosing.

CJC-1295 (no DAC) illustration
💉

Admin routes

Subcutaneous

📊

Popularity

Medium

Side effects

Generally mild

🏪

AU vendors

0 rated

Key benefits

1Preserves natural pulsatile GH release pattern
2Synergistic when combined with GHRP peptides like ipamorelin
3Shorter half-life reduces risk of sustained GH elevation
4Stimulates endogenous GH production rather than replacing it
5Does not suppress natural GH axis when used at moderate doses
6Well-tolerated with decades of GHRH analogue research

📈What to expect

1
Week 1–2

Improved sleep quality and deeper sleep stages

2
Week 2–4

Enhanced recovery between training sessions

3
Week 4–8

Improved skin quality, fat loss around midsection

4
Week 8–12

Measurable body composition changes; increased lean mass

Based on community reports and published research. Individual results vary significantly.

💊Dosing protocols

Anti-aging / recovery

Dose

100 mcg

Frequency

2–3 times daily (paired with ipamorelin)

Duration

8–12 weeks, then 4 weeks off

Body composition

Dose

100–200 mcg

Frequency

Pre-bed and post-training

Duration

12 weeks on, 4 weeks off

Sleep optimisation

Dose

100 mcg + 100 mcg ipamorelin

Frequency

Once nightly before bed

Duration

Ongoing with periodic breaks

Dosing information is sourced from published research and community protocols. This is not a recommendation. Consult a healthcare professional.

Research status|Preclinical - based on well-characterised GHRH physiology

Overview

CJC-1295 without DAC, commonly referred to as mod-GRF (1-29), is a synthetic analogue of the first 29 amino acids of growth hormone releasing hormone (GHRH). Unlike CJC-1295 with DAC, which binds to albumin for extended duration, the no-DAC version has a half-life of approximately 30 minutes. This shorter duration preserves the natural pulsatile pattern of GH release rather than causing sustained elevation. It is almost always used in combination with a GHRP (growth hormone releasing peptide) such as ipamorelin for synergistic effects.

⚙️How it works

Binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and release of growth hormone. The four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) protect against enzymatic degradation while maintaining receptor binding affinity. Because it mimics the natural GHRH signal, the resulting GH pulse follows physiological feedback loops - the pituitary still responds to somatostatin inhibition, preventing excessive GH levels.

Side effects

Flushing and warmth at injection site
mildCommon
Mild water retention
mildUncommon
Increased hunger (from GH pulse)
mildCommon
Tingling or numbness in extremities at higher doses
mildUncommon

📅Research history

1980s

GHRH (1-44) characterised; truncated GHRH (1-29) shown to retain full activity

1990s

Modified GRF (1-29) developed with four amino acid substitutions for stability

2000s

DAC version created for extended half-life; both versions studied

2010s

Mod-GRF + ipamorelin stack becomes dominant GH peptide protocol

2023

FDA cracks down on compounding pharmacies; availability shifts

Why 'no DAC' matters

The DAC (Drug Affinity Complex) version of CJC-1295 binds to albumin in the bloodstream, extending its half-life to 6-8 days. While this is convenient (fewer injections), it causes sustained GH elevation that does not mimic normal physiology. The pituitary naturally releases GH in pulses - especially during deep sleep. The no-DAC version triggers a single GH pulse per injection, which is why most protocols call for 2-3 daily injections timed around training and sleep.

The mod-GRF + ipamorelin stack

Combining mod-GRF (1-29) with ipamorelin is considered the standard GH peptide stack. Mod-GRF stimulates GH release via the GHRH pathway while ipamorelin does so via the ghrelin/GHS-R pathway. These two pathways are synergistic - the combined GH output is greater than either alone. Studies on GHRH + GHRP combinations show 2-3x greater GH release compared to either compound alone. This stack is preferred over straight GH because it preserves feedback regulation.

References

  1. [1]Ionescu M, Bhatt DL. 'Pharmacokinetics of modified GRF 1-29.' Growth Hormone & IGF Research, 2006.
  2. [2]Veldhuis JD, et al. 'Joint mechanisms of impaired growth-hormone pulse renewal in aging.' Journal of Clinical Endocrinology & Metabolism, 2009.

Frequently asked questions

Related peptides

Community experiences

Share your experience with CJC-1295 (no DAC). Effects, side effects, protocol details - help others make informed decisions.

Write a review

Rating:

No community reviews yet. Be the first to share your experience with CJC-1295 (no DAC).

Need to calculate your dose?

Use our free reconstitution calculator to work out syringe units for CJC-1295 (no DAC).

Open Calculator

Found this useful?

Share this guide

Disclaimer: This guide is for educational and informational purposes only. It is not medical advice. The dosing protocols listed are sourced from published research and community reports and do not constitute a recommendation. Always consult a qualified healthcare professional before using any peptide. Australian regulations classify many peptides as Schedule 4 (prescription-only) substances. Check current TGA guidelines before purchasing.